Nanotechnology advances in brain tumors: The state of the art

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 1, 2011, Pages 58-69

  Invernici, Gloria ^a   Cristini, Silvia ^a   Alessandri, Giulio ^a   Navone, Stefania E ^a   Canzi, Laura ^a   Tavian, Daniela ^b   Redaelli, Chiara ^b   Acerbi, Francesco ^a,c   Parati, Eugenio A ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer treatment; Drug delivery; Gene therapy; Nanoparticle; Nanotechnology; Patent

Indexed keywords

ALBUMIN; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CARBON NANOTUBE; CHITOSAN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GOLD NANOPARTICLE; HEPARIN; LIPOSOME; MAGNETIC NANOPARTICLE; MULTI WALLED NANOTUBE; NANOSHELL; POLYGLACTIN; POLYSORBATE 80; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; CANCER DIAGNOSIS; COMPOSITE MATERIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG PENETRATION; DRUG SPECIFICITY; GLIOBLASTOMA; GLIOMA; GOOD MANUFACTURING PRACTICE; HEALTH HAZARD; HUMAN; LIPOSOMAL DELIVERY; MOLECULAR IMAGING; NANOENCAPSULATION; NANOPROBE; NANOTECHNOLOGY; NANOTOXICOLOGY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NANOTECHNOLOGY;

EID: 78650959917     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211793979990     Document Type: Article

References (113)

1. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc 2007; 82: 1271-6.
2. Moffat BA, Reddy GR, McConville P, Hall DE, Chenevert TL, Kopelman RR, et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003; 2: 324-32.
3. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197: 533-8.
4. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma. Pharm Rev 2001; 53: 569-6.
5. Béduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-67.
6. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005; 5: 161-71.
7. Feng SS, Mu L, Win KY, Huang G. NPs of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004; 11: 413-24.
8. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
9. Olivier JC. Drug transport to brain with targeted NPs. NeuroRx 2005; 2: 108-19.
10. Bucci MK, Maity A, Janss AJ, Belasco JB, Fisher MJ, Tochner ZA, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: Results from a single center in the magnetic resonance imaging era. Cancer 2004; 101: 817-24.
11. Haglund MM, Hochman DW, Spence AM, Berger MS. Enhanced optical imaging of rat gliomas and tumor margins. Neurosurgery 1994; 35: 930-40.
12. Weissleder R. Molecular imaging in cancer. Science 2006; 312: 1168-71.
13. He J, Jones EF, vanBrocklin HF, Seo Y, Hanahan D, Franc BL. Nanoprobes for medical diagnosis and management: Current status of nanotechnology in molecular imaging. Curr Nanosci 2008; 4: 17-29.
14. Matsuura N, Rowlands JA. Towards new functional nanostructures for medical imaging. Med Phys 2008; 35: 4474-87.
15. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163: 871-8.
16. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006; 6: 669-76.
17. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, et al. Vascular targeted NPs for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12: 6677-86.
18. McFerrin MB, Sontheimer H. A role for ion channels in glioma cell invasion. Neuron Glia Biol 2006; 2: 39-49.
19. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005; 5: 1003-8.
20. Sun C, Lee JSH, Zhang MQ. Magnetic NPs in MR imaging and drug delivery. Adv Drug Deliv Rev 2008; 60: 1252-65.
21. Santra S, Zhang P, Wang K, Tapec R, Tan W. Conjugation of biomolecules with luminophore-doped silica NPs for photostable biomarkers. Anal Chem 2001; 73: 4988-93.
22. Makarova OV, Ostafin AE, Miyoshi H, Norris JR, Meisel D. Adsorption and encapsulation of fluorescent probes in NPs. J Phys Chem B 1999; 103: 9080-4.
23. Bikram, M. Ultrasmall superparamagnetic iron oxide NPs and uses thereof. US20100003197 (2010).
24. Schultz, S.E.A., Aslam, M., Dravid, V.P., Meade, T.J., Ulrich, B. Contrast agents. US20090269284 (2009).
25. Ham, S., Suh, J., Huh, Y., Yoon, H., Yang, J. Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance. US20090324494 (2009).
26. Lee S, Perez-Luna VH. Dextran-gold nanoparticle hybrid material for biomolecule immobilization and detection. Anal Chem 2005; 77: 7204-11.
27. Lian W, Litherland SA, Badrane H, Tan W, Wu D, Baker HV, et al. Ultrasensitive detection of biomolecules with fluorescent dye-doped NPs. Anal Biochem 2004; 334: 135-44.
28. Hoshino A, Hanaki KI, Suzuki K, Yamamoto K. Applications of Tlymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Commun 2004; 314: 46-53.
29. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99: 12617-24.
30. Zhukov, T.A., Ostapenko, S., Sutphen, R., Lancaster, J., Sellers, T.A., Zhang, J.Z. Luminescence characterization of quantum dots conjugated with biomarkers for early cancer detection. US7655479 (2010).
31. Toms, S.A., Lin, W. Methods of medical imaging using quantum dots. US20060173362 (2006).
32. Chen, J., Roa, W. Targeted NPs for cancer diagnosis and treatment. US20100034735 (2010).
33. Santra S, Liesenfeld B, Bertolino C, Dutta D, Cao Z, Tan W, et al. Fluorescence lifetime measurements to determine the core-shell nanostructure of FITC-doped silica NPs: an optical approach to evaluate nanoparticle photostability. J Lumin 2006; 117: 75-82.
34. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat Mater 2005; 4: 435-46.
35. Chan WCW, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281: 2016-28.
36. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005; 5: 709-11.
37. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel aVb3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63: 5838-43.
38. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial aVb3 integrin-targeted fumagillin NPs inhibit angiogenesis in atherosclerosis. Arterioscl Throm Vas Biol 2006; 26: 2103-9.
39. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by V 3-targeted magnetic resonance imaging. Nat Med 1998; 4: 623-6.
40. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, Gao MY. Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer. Adv Mater 2006; 18: 2553-6.
41. Zhang Q, Iwakuma N, Sharma P, Moudgil BM, Wu C, McNeill J, et al. Gold NPs as a contrast agent for in vivo tumor imaging with photoacoustic tomography. Nanotechnology 2009; 20: 395102.
42. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307: 538-44.
43. Jovin TM. Quantum dots finally come of age. Nat Biotechnol 2003; 21: 32-3.
44. Allen PM, Liu W, Chauhan VP, Lee J, Ting AY, Fukumura D, et al. In As(ZnCdS) quantum dots optimized for biological imaging in the near-infrared. J Am Chem Soc 2010; 132: 470-1.
45. Lee JE, Lee N, Kim H, Kim J, Choi SH, Kim JH, et al. Uniform mesoporous dye-doped silica NPs decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 2010; 132: 552-7.
46. Arndt-Jovin DJ, Kantelhardt SR, Caarls W, de Vries AHB, Giese A, Jovin TM. Tumor-targeted quantum dots can help surgeons find tumor boundaries. NanoBiosci IEEE Trans 2009; 8: 65-71.
47. Hickson J, Ackler S, Klaubert D, Bouska J, Ellis P, Foster K, et al. Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death Differ 2010; 17: 1003-10.
48. Orringer DA, Koo YE, Chen T, Kim G, Hah HJ, Xu H, et al. In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation. Neurosurgery 2009; 64: 965-72.
49. Hwang Do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010; 51: 98-105.
50. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009; 69: 6200-7.
51. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007; 67: 6882-8.
52. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 2004; 15: 1062-7.
53. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122: 598-609.
54. Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchianò A, et al. A novel intraarterial chemotherapy using paclitaxel in albumin NPs to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol 2003; 181: 253-60.
55. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan NPs. Pharm Res 2002; 19: 998-1008.
56. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and NPs: Effects of molecular weight and degree of deacetylation. Pharm Res 2004; 21: 344-53.
57. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) NPs: Implications for drug and gene delivery. FASEB J 2002; 16: 1217-26.
58. Weissenböck A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: Preparation and association with Caco-2 single cells. J Control Release 2004; 99: 383-92.
59. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid NPs as a function of the lipid matrix and the surfactant. Pharm Res 1997; 14: 458-62.
60. Muller RH, Mader K, Gohla S. Solid lipid NPs (SLN) for controlled drug delivery: A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
61. Wissing SA, Kayser O, Müller RH. Solid lipid NPs for parental drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-72.
62. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel NPs for the potential treatment of brain tumors. J Control Release 2004; 99: 259-69.
63. Gupta M, Gupta AK. In vitro cytotoxicity studies of hydrogel pullulan NPs prepared by AOT/N-hexane micellar system. J Pharm Pharm Sci 2004; 7: 38-46.
64. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold NPs to enhance radiotherapy in mice. Phys Med Biol 2004; 49: 309-15.
65. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, et al. Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11: 169-83.
66. Cruz T, Gaspar R, Donato A, Lopes C. Interaction between polyalkylcyanoacrylate NPs and peritoneal macrophages: MTT metabolism, NBT reduction and NO production. Pharm Res 1997; 14: 73-9.
67. Olivier JC, Fenart L, Chauvet R, Pariat C, Cechelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate NPs is related to toxicity. Pharm Res 1999; 16: 1836-42.
68. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) NPs deliver drugs of the CNS via specific mechanisms requiring prior binding of drug to the NPs. Pharm Res 2003; 20: 409-16.
69. Gupta AK, Gupta M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic NPs. Biomaterials 2005; 26: 1565-73.
70. Kim SY, Lee YM, Baik DJ, Kang JS. Toxic characteristics of methoxy poly(ethylene glycol)/poly(-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 2003; 24: 55-63.
71. Cascone MG, Lazzeri L, Carmignani C, Zhu Z. Gelatin NPs produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med 2002; 13: 523-6.
72. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic NPs for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-6.
73. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric NPs for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008; 5: 155-74.
74. Kreuter J. Nanoparticlate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
75. Calvo P, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP. Long-circulating PEGylated polycyanoacry late NPs as new drug carrier for brain delivery. Pharm Res 2001; 18: 1157-66.
76. Kreuter, J., Gelperina, S., Maksimenko, O., Khalanskiy, A. Polylactide NPs. US20090263491 (2009).
77. Bae, Y.H., Lee, E.S., Kim, D., Youn, Y.S. Oh, K.T. Drug delivery vehicle that mimics viral properties. US20090060955 (2009).
78. Lowman, A.M., Vardon, V., Schuster, J. Local delivery system for the chemotherapeutic drug paclitaxel. US20090304771 (2009).
79. Albrecht, R.M., Kandela, I. Colloidal magnetic nanobioparticles for cytotoxicity and drug delivery. US20090136582 (2009).
80. Labhasetwar, V.D., Sahoo, S.K. Transferrin-conjugated NPs for increasing efficacy of a therapeutic agent. US20100015051 (2010).
81. Sabel, B., Walz, C., Ringe, K. Use of NPs for the DNA administration to a target organ. US7402573 (2008).
82. Mikhail AS, Allen C. Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J Control Release 2009; 138: 214-23.
83. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103: 11838-43.
84. Liu JW, Lu Y. Fast colorimetric sensing of adenosine and cocaine based on a general sensor design involving aptamers and NPs. Angew Chem Int Ed 2006; 45: 90-4.
85. Wu Y, Sefah K, Liu H, Wang R, Tan W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 2010; 107: 5-10.
86. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-80.
87. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, et al. Distribution of liposomes into brain and rat brain tumor models by convection enhanced delivery monitored with magnetic resonance imaging. Cancer Res 2004; 64: 2572-9.
88. Ren H, Boulikas T, Lundstrom K, Söling A, Warnke PC, Rainov NG. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol 2003; 64: 147-54.
89. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma. Hum Gene Ther 1998; 9: 2595-604.
90. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-401.
91. Boulikas, P. Cancer treatments. US20090053302 (2009).
92. Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009; 8: 2674-83.
93. Franzen, S., Guenther, R., Lommel, S.A., Loo, L. Viral nanoparticle cell-targeted delivery platform. WO2008153725 (2008).
94. VanHandel M, Alizadeh D, Zhang L, Kateb B, Bronikowski M, Manohara H, et al. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J Neuroimmunol 2009; 208: 3-9.
95. Kateb B, Van Handel M, Zhang L, Bronikowski MJ, Manohara H, Badie B. Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors. Neuroimage 2007; 37: S9-S17.
96. Dai, H., Liu, Z., Li, X., Sun, X. Supramolecular functionalization of graphitic NPs for drug delivery. US20090087493 (2009).
97. Owens, D.E., Peppas, N.A. Temperature-sensitive NPs for controlled drug delivery. US20080138430 (2008).
98. van Vlerken LE, Amiji MM. Multi-functional polymeric NPs for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006; 3: 205-16.
99. Wu, A., Paunesku, T., Woloschak, G.E. Multifunction nanocon jugates for imaging applications and targeted treatment. US20090263331 (2009).
100. Rajh, T., Paunesku, T., Woloschak, G.E., Thurnauer, M.C. Dopa and dopamine modification of metal oxide semiconductors, method for attaching biological molecules to semiconductors. US6677606 (2004).
101. Mukherjee, P., Bhattacharya, R., Mukhopadhyay, D. NPs for therapeutic and diagnostic applications. US20060222595 (2006).
102. West, J.L., Halas, N.J., Hirsch, L.R. Optically-active NPs for use in therapeutic and diagnostic methods. US20020103517 (2002).
103. Rand, R.W. Inductive heating process for use in causing necrosis of neoplasms at selective frequencies. US4983159 (1991).
104. Yingling, Y.G., Shapiro, B.A. RNA NPs and Nanotubes. US 20100016409 (2010)
105. Hainfeld, J. F., Slatkin, D.N. Methods of enhancing radiation effects with metal NPs. US7530940 (2003).
106. Guo, T. Nanoparticle radiosensitizers. US20080003183 (2008).
107. Moon S, Kim DJ, Kim K, Kim D, Lee H, Lee K, et al. Surface enhanced plasmon resonance detection of nanoparticle-conjugated DNA hybridization. Appl Opt 2010; 49: 484-91.
108. Borm PJ, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 2006; 3: 11.
109. Schnyder A, Krahenbuhl, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 2005; 13: 325-35.
110. Raffaghello L, Zuccari G, Carosio R, Orienti I, Montaldo PG. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4). Clin Cancer Res 2006 12: 3485-9.
111. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, et al. The effect of thermotherapy using magnetic NPs on rat malignant glioma. J Neurooncol 2006; 78: 7-14.
112. Farokhzad OC, Langer R. Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58: 1456-9.
113. Brigger I, Dubernet C, Couvreur P. NPs in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631-51